America Great Health (AAGH)
USD 0.0
(-18.18%)
USD 0.0
(-18.18%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 1.81 Million USD | 45.6% |
| 2022 | 1.24 Million USD | 298.57% |
| 2021 | 312.95 Thousand USD | 86.43% |
| 2020 | 167.86 Thousand USD | 30.83% |
| 2019 | 128.3 Thousand USD | 27.65% |
| 2018 | 100.51 Thousand USD | 149.62% |
| 2017 | 40.26 Thousand USD | -92.51% |
| 2016 | 537.3 Thousand USD | 3863.7% |
| 2015 | -14.27 Thousand USD | 0.0% |
| 2014 | - USD | -100.0% |
| 2013 | 155.62 Thousand USD | 1576.04% |
| 2012 | 9285.00 USD | 238.07% |
| 2011 | -6725.00 USD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q3 | 1.78 Million USD | 2.27% |
| 2024 Q1 | 1.78 Million USD | -1.87% |
| 2024 Q2 | 1.74 Million USD | -1.83% |
| 2023 Q3 | 1.76 Million USD | 31.42% |
| 2023 FY | 1.81 Million USD | 45.6% |
| 2023 Q4 | 1.81 Million USD | 3.15% |
| 2023 Q1 | 1.28 Million USD | 3.18% |
| 2023 Q2 | 1.33 Million USD | 4.1% |
| 2022 Q3 | 1.17 Million USD | 15.74% |
| 2022 FY | 1.24 Million USD | 298.57% |
| 2022 Q4 | 1.24 Million USD | 6.15% |
| 2022 Q2 | 1.01 Million USD | 34.51% |
| 2022 Q1 | 754.74 Thousand USD | 141.17% |
| 2021 Q3 | 113.95 Thousand USD | 28.5% |
| 2021 Q2 | 88.68 Thousand USD | -47.87% |
| 2021 Q4 | 312.95 Thousand USD | 174.63% |
| 2021 FY | 312.95 Thousand USD | 86.43% |
| 2021 Q1 | 170.11 Thousand USD | 1.34% |
| 2020 Q1 | 131.1 Thousand USD | 2.19% |
| 2020 Q2 | 143.66 Thousand USD | 9.57% |
| 2020 Q3 | 145.41 Thousand USD | 1.22% |
| 2020 FY | 167.86 Thousand USD | 30.83% |
| 2020 Q4 | 167.86 Thousand USD | 15.44% |
| 2019 Q1 | 100.61 Thousand USD | 0.1% |
| 2019 FY | 128.3 Thousand USD | 27.65% |
| 2019 Q3 | 127.27 Thousand USD | 2.26% |
| 2019 Q4 | 128.3 Thousand USD | 0.81% |
| 2019 Q2 | 124.46 Thousand USD | 23.71% |
| 2018 Q1 | 47.23 Thousand USD | 17.32% |
| 2018 Q3 | 70.86 Thousand USD | 7.34% |
| 2018 FY | 100.51 Thousand USD | 149.62% |
| 2018 Q4 | 100.51 Thousand USD | 41.84% |
| 2018 Q2 | 66.01 Thousand USD | 39.75% |
| 2017 Q2 | -4057.00 USD | -100.68% |
| 2017 FY | 40.26 Thousand USD | -92.51% |
| 2017 Q4 | 40.26 Thousand USD | 237.65% |
| 2017 Q3 | 11.92 Thousand USD | 393.94% |
| 2017 Q1 | 598.86 Thousand USD | 11.46% |
| 2016 Q2 | 475.99 Thousand USD | 534.28% |
| 2016 Q3 | 511.57 Thousand USD | 7.47% |
| 2016 Q4 | 537.3 Thousand USD | 5.03% |
| 2016 Q1 | 75.04 Thousand USD | 625.67% |
| 2016 FY | 537.3 Thousand USD | 3863.7% |
| 2015 Q4 | -14.27 Thousand USD | -14.35% |
| 2015 Q2 | -39.57 Thousand USD | 0.0% |
| 2015 Q1 | - USD | 0.0% |
| 2015 FY | -14.27 Thousand USD | 0.0% |
| 2015 Q3 | -12.48 Thousand USD | 68.45% |
| 2014 Q2 | - USD | -100.0% |
| 2014 Q1 | 81.86 Thousand USD | -47.4% |
| 2014 Q3 | - USD | 0.0% |
| 2014 Q4 | - USD | 0.0% |
| 2014 FY | - USD | -100.0% |
| 2013 Q2 | 145.29 Thousand USD | 7.51% |
| 2013 Q4 | 155.62 Thousand USD | 29.86% |
| 2013 FY | 155.62 Thousand USD | 1576.04% |
| 2013 Q1 | 135.13 Thousand USD | 35569.03% |
| 2013 Q3 | 119.83 Thousand USD | -17.52% |
| 2012 Q4 | -381.00 USD | -108.4% |
| 2012 Q3 | 4534.00 USD | 0.0% |
| 2012 FY | 9285.00 USD | 238.07% |
| 2011 FY | -6725.00 USD | 0.0% |
| 2011 Q4 | -6725.00 USD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Ampio Pharmaceuticals, Inc. | -3.81 Million USD | 147.605% |
| Aridis Pharmaceuticals, Inc. | 1.25 Million USD | -44.826% |
| Biora Therapeutics, Inc. | 32.21 Million USD | 94.362% |
| Bio-Path Holdings, Inc. | -939 Thousand USD | 293.41% |
| Better Therapeutics, Inc. | -860 Thousand USD | 311.177% |
| Calithera Biosciences, Inc. | -23.78 Million USD | 107.636% |
| Comera Life Sciences Holdings, Inc. | 328.44 Thousand USD | -452.952% |
| Gene Biotherapeutics, Inc. | - USD | -Infinity% |
| eFFECTOR Therapeutics, Inc. | 4.57 Million USD | 60.26% |
| Eloxx Pharmaceuticals, Inc. | -5.82 Million USD | 131.189% |
| Evelo Biosciences, Inc. | 3.19 Million USD | 43.211% |
| Evolutionary Genomics, Inc. | 3.16 Million USD | 42.649% |
| Finch Therapeutics Group, Inc. | 5 Million USD | 63.692% |
| Galera Therapeutics, Inc. | 134.04 Million USD | 98.645% |
| Innovation1 Biotech Inc. | 179.15 Thousand USD | -913.744% |
| Kiromic BioPharma, Inc. | 12.33 Million USD | 85.281% |
| Molecular Templates, Inc. | 707 Thousand USD | -156.877% |
| Navidea Biopharmaceuticals, Inc. | 438.44 Thousand USD | -314.22% |
| NexImmune, Inc. | -3.13 Million USD | 157.956% |
| Orgenesis Inc. | 21.78 Million USD | 91.663% |
| Panbela Therapeutics, Inc. | 2.61 Million USD | 30.576% |
| Point of Care Nano-Technology, Inc. | -498.00 USD | 364783.133% |
| PaxMedica, Inc. Common Stock | -4.71 Million USD | 138.554% |
| Scopus BioPharma Inc. | -124.57 Thousand USD | 1557.854% |
| Sorrento Therapeutics, Inc. | 110.87 Million USD | 98.362% |
| Statera Biopharma, Inc. | 14.41 Million USD | 87.402% |
| TRACON Pharmaceuticals, Inc. | -7.59 Million USD | 123.909% |
| Trevena, Inc. | 2.25 Million USD | 19.569% |
| Vaxxinity, Inc. | 10.13 Million USD | 82.075% |
| Vaccinex, Inc. | -1.28 Million USD | 241.003% |
| Vicapsys Life Sciences, Inc. | 344.44 Thousand USD | -427.259% |
| Viracta Therapeutics, Inc. | 13.23 Million USD | 86.282% |
| ZIVO Bioscience, Inc. | 71.96 Thousand USD | -2423.724% |